DEVELOPMENT PRODUCTS Sample Clauses

DEVELOPMENT PRODUCTS. 8.1 The parties recognize that various design change requests ("DCRs"), such as modifications, design changes, redesigns, and manufacturing process improvements may be made to Capstone Special Order PSRs during the term of this Agreement. A) DCRs not affecting the form, fit, function, or safety of Capstone Special Order PSRs and which DCRs do not involve or require increased technical risk, tooling changes, field retrofit, or more than 5% part cost increase ("Type 1 DCRs") may be requested by either party for, approval by the other party, which approval shall not be unreasonably withheld. If the non-requesting party approves such Type 1 DCR, the Capstone Special Order PSRs shall be modified as required to incorporate and implement such Type 1 DCR. B) DCRs relating to new, re-designed, or substantially modified PSRs or DCRs which involve or require increased technical risk, tooling changes, field retrofit, or more than 5% part cost increase, shall be referred to as "Type 2 DCRs". Type 2 DCRs initiated by Solar may be disclosed to Capstone at Solar's sole option and discretion for possible inclusion of Capstone Special Order PSRs incorporating and implementing such Type 2 DCRs under the terms of this Agreement. Type 2 DCRs initiated by Capstone must be promptly disclosed to Solar to allow Solar a right of first refusal to manufacture the resulting new Capstone Special Order PSRs incorporating and implementing such Type 2 DCRs under the provisions of this Agreement. If new Capstone Special Order PSRs are agreed upon under the terms of this sub-paragraph 8.1 (B), the parties shall add such new Capstone Special Order PSRs to this Agreement and update Exhibits A and B as provided for in Paragraph 8.2.
View SourceView Similar (3)
DEVELOPMENT PRODUCTS. Products required to make or connect a medical endoscope embodying the Technology to video cameras or other electronic imaging devices. Products and processes necessary to manufacture and market 3-D Video Systems utilizing the Technology, which systems include (1) an endoscope utilizing the Technology (2) a coupler or other means of attachment, alignment and integration of the endoscope with the remainder of the system, (3) two video cameras, (4) a suitable light source and its cables, connectors and the like, and (5) a video display system using video switching or other appropriate technology, resulting in the display of an apparent three-dimensional image of the object being viewed with the endoscope. -------------------------------------------------------------------------------- ▇▇▇▇▇▇▇▇ OPTICS, INC. FAX: (▇▇▇) ▇▇▇-▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ TEL: (▇▇▇) ▇▇▇-▇▇▇▇ ▇.▇. ▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ -------------------------------------------------------------------------------- June 28, 1994 AMERICAN SURGICAL TECHNOLO ▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ATTN: ▇▇▇ ▇▇▇▇▇ This letter constitutes an Agreement to alter the provisions of the LICENSE AND DEVELOPMENT AGREEMENT between ▇▇▇▇▇▇▇▇ OPTICS, Inc. and AMERICAN SURGICAL TECHNOLOGIES CORPORATION, dated December 18, 1991. For Paragraph 3.1(c)(i) substitute the following:
View SourceView Similar (2)
DEVELOPMENT PRODUCTS. With respect to units of the Aject to be used for research, development, and clinical testing within the scope of the Aject Development Plan and the AngioSense Product Development Plan and in accordance with Article 5 of this Agreement II, Bioject agrees to transfer the Aject (alone or to be used as part of the AngioSense Product) free of charge; provided, however AngioSense shall be responsible for all shipping and insurance charges for such as set forth in Section 8.7 above. Notwithstanding anything herein to the contrary, Bioject shall be obligated to supply only those quantities of the Aject for use within the scope of the Aject Development Plan and the AngioSense Development Plan as reasonably determined by the Joint Development Committee. All units of the Ajects supplied to AngioSense under this Section 9.1.2 shall not be used for any other purpose.
View SourceView Similar (2)
DEVELOPMENT PRODUCTS. GEI disclaims any and all warranties for all items not yet released to GEI's general customer base, including, but not limited to, items which are still in development in its current (as of the shipment date) Price Book, or as otherwise identified as unreleased items to the Customer.
View Source
DEVELOPMENT PRODUCTS. As soon as is mutually convenient for the -------------------- parties, Pharmos and BLP agree to use good faith efforts to prepare a mutually agreeable research and development plan for each Development Product (each an "R&D PLAN") similar in form and content previously agreed to in the U.S. Marketing Agreement. If the parties shall not have agreed on the R&D Plan for a particular Development Product for the New Territories after good faith efforts, the parties shall resolve their disagreement in the manner contemplated by the U.S. Marketing Agreement. The parties further agree that the failure to agree on an R&D Plan or the failure of BLP to perform its obligations under Section 4.5 below shall have the consequences set forth in Section 5.7 of the U.S. Marketing Agreement.
View Source
DEVELOPMENT PRODUCTS. As soon as is mutually convenient for the parties, Pharmos and BLP agree to use good faith efforts to prepare a mutually agreeable research and development plan for each Development Product (each an "R&D Plan"). Each R&D Plan shall be of scope customary in the trade for the development of new drug compounds, and shall include without limitation proposed formulations, safety and efficacy targets and anticipated budgets. If the parties shall not have agreed on the R&D Plan for a particular Development Product after good faith efforts, the parties shall submit their respective positions on such R&D Plan to a mutually agreeable consultant with relevant expertise with ophthalmic drug products for recommendations on the matter(s) in dispute, which recommendations shall be approved by both parties in their reasonable discretion.
View Source
DEVELOPMENT PRODUCTS. Prior to the beginning of the [***] year of commercialization of a Development Products, the Parties will agree to an allocation of the Development Product that may be disposed of [***] to their distributors and subdistributors. Development Product provided [***] by PBM shall be at PBM’s expense. Development Product provided by NANOGEN [***] shall be charged by and payable to PBM by NANOGEN at $[***] for a single analyte test and $[***] for a double window test and multiples of $[***] for each analyte in a panel. Development Product provided under this Section shall not exceed more than [***] percent ([***]%) of the Developed Product actually sold by PBM and NANOGEN in any twelve (12) month period.
View Source
DEVELOPMENT PRODUCTS. The parties agree that any sale by Accuray to a customer in the Homeland Security Market of development units of Traveling Wave Products provided for engineering and/or evaluation purposes and not for commercial use shall not be considered a sale to a Commercial Customer for the purposes of Sections 1 and 2 above.
View Source
DEVELOPMENT PRODUCTS. In any relevant Project SOW, based on Genzyme’s final Product formulations, concentration, fill volumes, and the Parties’ agreement to the final Product Specifications, Hospira will Manufacture Development Products at the prices set forth in the relevant Project SOW. Genzyme shall issue a Purchase Order for any such Development Product(s) at least [**] days before the requested delivery date. Genzyme and Hospira shall agree mutually to the formulation, concentration, fill volume and the components for each lot of Development Product(s).
View Source

Related to DEVELOPMENT PRODUCTS

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time